Markets


Aurinia Pharmaceuticals Inc (AUPH) Announces Clinical Development for New Indications

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) shares are rising nearly 4% in pre-market trading Friday, after the drug maker announced plans to expand its voclosoprin renal …

Analysts Chime in on Celgene Corporation (CELG) Crohn’s Dud and Gilead Sciences, Inc. (GILD) Winning FDA Nod for Yescarta

Cowen always deemed CELG’s failed drug a risky contender, welcomes GILD’s full approval for Yescarta.

Omeros Corporation (OMER) Case Report Presented at EBMT Annual Meeting

Omeros Corporation (NASDAQ:OMER) announced the presentation of a case report of a patient having co-existing hematopoietic stem cell transplant-associated thrombotic microangiopathy (HCT-TMA) and …

Cantor Sheds Light on Teva Pharmaceutical Industries Ltd (ADR) (TEVA) as Novartis (NVS) Facing the Generics Pricing Heat

Louise Chen anticipates more generic pricing pressure hit 3Q earnings for generic manufacturers.

Top Analyst Says Look for Strong Revenue Growth from Facebook Inc (FB) Come 3Q Earnings Time

Youssef Squali believes strong monetization and user growth have treated FB well during the quarter.

Cowen Shines Light on Uniqure NV (QURE) as the Latter Advances Padua Variant AMT-061 into Phase 3

Uniqure NV is back in the race for a hemophilia B gene therapy.

‘Stock Market Wizard’ Michael Masters Puts His Money on Transenterix Inc (TRXC), Says Bye Bye to Gilead Sciences, Inc. (GILD)

Did this $4 billion fund make the right call on these two soaring biotechs?

Alcobra Ltd (ADHD) Stock Fires Up To The Roof; Here’s Why

Alcobra Ltd (NASDAQ:ADHD) is a mover and shaker out on the Street today, with investors sparking the stock on an almost 40% upturn. …

Micron Technology, Inc. (MU) Can Rise on Back of Short-Term NAND Supply Tightness, Apple Inc. (AAPL) Watch Series 3 Poised to Be a Holiday Gains Maker

Harlan Sur: MU at a key NAND advantage; Daniel Ives: AAPL attracting new customers to buy Apple Watches.

Imprimis Pharmaceuticals Inc (IMMY) Stock: Gaining On Generic Version of Restasis

It’s a very rewarding trading day for investors in Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) with shares up over 70%, making the stock Wall Street’s …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts